These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000483-27 Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial. 2008-01-28 due-trials
Completed, but no date, and reported results 2004-000766-12 Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial bad-data
Reported results 2004-001748-66 Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, de la eficacia y seguridad de BIA 2-093 como tratamiento complementario en las crisis parciales re... 2008-01-22 due-trials
Ongoing 2004-004317-42 Ensayo clínico aleatorizado, doble ciego, doble dummy, controlado con placebo, para valorar la eficacia y seguridad de diferentes presentaciones de inmunoterapia subcutánea en pacientes asmáticos sens... not-yet-due
Reported results 2005-002131-27 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, RANDOMISED, DOSE-TITRATION, PLACEBO-CONTROLLED, MULTICENTRE CLI... 2007-01-12 due-trials
Reported results 2005-002133-13 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, FIXED MULTIPLE DOSE, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTR... 2006-11-13 due-trials
Reported results 2005-002134-35 EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER 2007-07-19 due-trials
Reported results 2006-001793-24 A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON T... 2007-09-21 due-trials
Reported results 2007-001887-55 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN CHILDREN: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICEN... 2017-08-24 due-trials
Reported results 2007-002461-12 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS THERAPY FOR PATIENTS WITH PAINFUL DIABETIC NEUROPATHY: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI... 2010-03-25 due-trials
Reported results 2007-002473-31 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENT... 2010-05-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-002455-25 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL‑GROUP, MULTICENTR... 2018-05-16 bad-data
Reported results 2008-003557-32 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS THERAPY IN PATIENTS WITH FIBROMYALGIA: A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL 2010-09-02 due-trials
Reported results 2008-003736-38 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS PREVENTIVE THERAPY FOR PATIENTS WITH MIGRAINE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAL 2010-06-14 due-trials
Reported results 2008-003869-72 A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE... 2010-02-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-005606-39 EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINI... 2015-04-06 bad-data
Reported results 2009-011135-13 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI... 2016-09-08 due-trials
Reported results 2009-012587-14 SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS 2013-10-08 due-trials
Reported results 2009-012897-12 A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltra... 2010-06-24 due-trials
Reported results 2010-019100-23 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain 2012-04-24 due-trials
Reported results 2010-019101-42 A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia 2012-04-24 due-trials
Reported results 2010-021860-13 EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED,... 2014-12-17 due-trials
Reported results 2010-022366-27 Efficacy and safety of BIA 9-1067 in idiopathic Parkinson’s disease patients with “wearing-off” phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a double-blind, randomised,... 2013-06-13 due-trials
Reported results 2011-000814-21 A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma sens... 2013-04-22 due-trials
Reported results 2011-004583-30 A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVI... 2012-11-30 due-trials
Exempt 2012-000672-42 Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them. ESTANDARIZACIÓN BIOLÓG... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-001091-11 OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ... 2020-04-03 bad-data
Reported results 2012-003137-41 DOUBLE-BLIND STUDY IN PAEDIATRIC EPILEPTIC SUBJECTS AGED FROM 5 TO LESS THAN 8 YEARS TO COMPARE THE SUBJECT PREFERENCE FOR ESL SUSPENSION FORMULATION WITH ALTERNATIVE FLAVOURS 2012-12-31 due-trials
Reported results 2014-001459-22 OPEN CLINICAL TRIAL, MULTICENTER, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PATIENTS WITH ALLERGY RHINOCONJUNCTIVITIS SENSITIZED TO PARIETARIA JUDAICA ENSAYO CLÍNICO ABIERTO, MULTIC... 2016-03-11 due-trials
Reported results 2015-001243-36 EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI... 2019-03-19 due-trials
Reported results 2016-001072-29 OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ... 2021-05-11 due-trials
Reported results 2016-002391-27 Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations 2018-07-04 due-trials
Not reported Terminated 2016-002944-18 MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC RHIN... 2017-04-10 due-trials
Listed as ongoing, but also has a completion date 2018-002448-10 An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH) 2021-10-20 bad-data
Listed as ongoing, but also has a completion date 2018-002747-29 Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate 2023-09-11 bad-data
Listed as ongoing, but also has a completion date 2018-002796-18 An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease 2022-02-17 bad-data
Listed as ongoing, but also has a completion date 2020-001175-32 Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. 2024-02-16 bad-data
Completed, report not yet due 2020-001176-15 Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders. 2023-03-29 not-yet-due
Listed as ongoing, but also has a completion date 2020-002754-24 A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study to evaluate the add-on effect of opicapone 50 mg or levodopa 100 mg as first strategy for the treatm... 2023-04-18 bad-data
Listed as ongoing, but also has a completion date 2020-005011-52 A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inh... 2024-01-26 bad-data